JP4963607B2 - 神経再生及び機能回復のためのシグマリガンド - Google Patents

神経再生及び機能回復のためのシグマリガンド Download PDF

Info

Publication number
JP4963607B2
JP4963607B2 JP2006533806A JP2006533806A JP4963607B2 JP 4963607 B2 JP4963607 B2 JP 4963607B2 JP 2006533806 A JP2006533806 A JP 2006533806A JP 2006533806 A JP2006533806 A JP 2006533806A JP 4963607 B2 JP4963607 B2 JP 4963607B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
sigma
administration
functional recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006533806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500757A5 (https=
JP2007500757A (ja
Inventor
オクセンバーグ，ドナ
アーファー，ローマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MS Science Corp
Original Assignee
MS Science Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MS Science Corp filed Critical MS Science Corp
Publication of JP2007500757A publication Critical patent/JP2007500757A/ja
Publication of JP2007500757A5 publication Critical patent/JP2007500757A5/ja
Application granted granted Critical
Publication of JP4963607B2 publication Critical patent/JP4963607B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006533806A 2003-06-12 2004-06-14 神経再生及び機能回復のためのシグマリガンド Expired - Fee Related JP4963607B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US47873503P 2003-06-12 2003-06-12
US47832903P 2003-06-12 2003-06-12
US60/478,329 2003-06-12
US60/478,735 2003-06-12
US49813203P 2003-08-26 2003-08-26
US60/498,132 2003-08-26
US55261304P 2004-03-12 2004-03-12
US60/552,613 2004-03-12
PCT/US2004/019139 WO2004110387A2 (en) 2003-06-12 2004-06-14 Sigma ligands for neuronal regeneration and functional recovery

Publications (3)

Publication Number Publication Date
JP2007500757A JP2007500757A (ja) 2007-01-18
JP2007500757A5 JP2007500757A5 (https=) 2007-07-26
JP4963607B2 true JP4963607B2 (ja) 2012-06-27

Family

ID=33556648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533806A Expired - Fee Related JP4963607B2 (ja) 2003-06-12 2004-06-14 神経再生及び機能回復のためのシグマリガンド

Country Status (5)

Country Link
US (4) US20050032827A1 (https=)
EP (2) EP1644026A4 (https=)
JP (1) JP4963607B2 (https=)
CA (1) CA2528160C (https=)
WO (3) WO2004110387A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061658A1 (en) * 2002-01-22 2003-07-31 Eisai Co., Ltd. Sigma receptor binder containing indanone derivative
US20050032827A1 (en) * 2003-06-12 2005-02-10 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
US20060052386A1 (en) * 2003-06-12 2006-03-09 Tadeusz Wieloch Sigma ligands for neuronal regeneration and functional recovery
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
US20060106064A1 (en) * 2004-11-03 2006-05-18 University Of North Texas Health Science Center At Fort Worth Butyrophenones and sigma-1 receptor antagonists protect against oxidative-stress
CA2607598A1 (en) * 2005-06-06 2006-12-14 University Of South Florida Treatment with sigma receptor agonists post-stroke
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7985751B2 (en) 2005-08-09 2011-07-26 M's Science Corporation Piperazine derivatives
US7758954B2 (en) * 2005-08-18 2010-07-20 James Hardie Technology Limited Coated substrate having one or more cross-linked interfacial zones
US20070142396A1 (en) * 2005-12-16 2007-06-21 Vela Pharmaceuticals, Inc. Treatment of pain with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone or salt thereof
WO2007081946A2 (en) * 2006-01-09 2007-07-19 University Of South Florida Method for the identification of drugs to treat stroke at delayed timepoints
NZ570078A (en) 2006-01-27 2011-10-28 Ms Science Corp Piperidine and piperazine derivatives
AU2009217031B2 (en) * 2008-02-18 2013-12-19 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy
CN101970427A (zh) 2008-02-29 2011-02-09 Vm生物医药公司 治疗疼痛症状及其它失调的方法
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
WO2010048164A2 (en) * 2008-10-20 2010-04-29 University Of South Florida N,n'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints
AU2009310926A1 (en) * 2008-10-27 2010-05-06 M's Science Corporation Cyclohexylamine derivative containing phenyl group, and therapeutic agent for diseases accompanied by central nervous system disorders
SG10201404913QA (en) 2009-04-09 2014-11-27 Cognition Therapeutics Inc Inhibitors of cognitive decline
RU2012107457A (ru) 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
WO2011130347A2 (en) * 2010-04-13 2011-10-20 The Johns Hopkins University Methods for enhancing axonal regeneration
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
CA2846611A1 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
KR101129303B1 (ko) * 2011-10-19 2012-03-26 경희대학교 산학협력단 플루옥세틴을 유효성분으로 함유하는 중추신경계 질환의 예방 및 치료용 약학적 조성물
WO2013166307A2 (en) * 2012-05-02 2013-11-07 University Of South Florida N,n'-di-1 naphthylguanidine hcl (nagh) and n,n'-di-p-nitrophenylguanidine hcl (nad) treatment for stroke at delayed timepoints
CN104519891B (zh) 2012-05-16 2019-03-22 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
TW201607538A (zh) 2013-12-17 2016-03-01 以斯提夫博士實驗室股份有限公司 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
EP3364976B1 (en) * 2015-10-19 2026-03-18 Board of Regents, The University of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
US11129801B2 (en) * 2016-02-11 2021-09-28 Sigmathera Sas Igmesine for use in the treatment of neurodegenerative diseases
AU2017257153A1 (en) 2016-04-29 2018-11-22 Board Of Regents, The University Of Texas System Sigma receptor binders
EP3634394B1 (en) 2017-05-15 2025-12-24 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
EP3684463B1 (en) 2017-09-19 2025-05-14 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020047185A1 (en) * 2018-08-31 2020-03-05 Texas Tech University System Enhancers of neurolysin activity
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法
CN111848549B (zh) * 2019-04-29 2022-04-22 苏州大学 芳基肟类化合物及其制备和应用
WO2022125925A1 (en) * 2020-12-11 2022-06-16 Cognition Therapeutics, Inc. Compositions for treating dry age-related macular degeneration (amd)
CN117979972A (zh) * 2021-09-20 2024-05-03 埃斯特韦制药股份公司 用于治疗运动神经元退化或神经保护的氧杂二氮杂螺化合物
US20250134902A1 (en) * 2022-02-09 2025-05-01 Univesrity Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5109002A (en) 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
US5005470A (en) * 1989-11-09 1991-04-09 Denker James G Portable work station
US5229394A (en) 1990-07-30 1993-07-20 Arch Development Corporation Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
WO1993009094A1 (en) 1991-10-30 1993-05-13 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
US5428037A (en) 1993-04-09 1995-06-27 Syntex Pharmaceuticals, Ltd. Heterocyclic derivatives in the treatment of Ischaemia and related diseases
CA2166100A1 (en) * 1993-06-23 1995-01-05 Richard A. Glennon Sigma receptor ligands and the use thereof
EP0711763B1 (en) * 1993-07-28 2000-10-18 Santen Pharmaceutical Co., Ltd. 1,4-di(phenylalkyl)piperazine derivatives
GB9416571D0 (en) 1994-08-16 1994-10-12 Battelle Memorial Institute Novel alkylamino derivatives as sigma 2 selective ligands
UA64769C2 (uk) 1997-11-07 2004-03-15 Х. Луннбек А/С Гідрогалогеніди 1'-[4-[1-(4-фторофеніл)-1н-індол-3-іл]-1-бутил]-спіро[ізобензофуран-1(3н),4'-піперидину], фармацевтична композиція та спосіб лікування
CN1296409A (zh) * 1998-04-07 2001-05-23 H·隆德贝克有限公司 恐慌发作的治疗
US20030087840A1 (en) * 1998-05-19 2003-05-08 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
GB0007842D0 (en) * 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US7829562B2 (en) * 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
US20060052386A1 (en) 2003-06-12 2006-03-09 Tadeusz Wieloch Sigma ligands for neuronal regeneration and functional recovery
US20050032827A1 (en) 2003-06-12 2005-02-10 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery

Also Published As

Publication number Publication date
WO2004110387A3 (en) 2005-08-18
EP1635805A4 (en) 2007-08-08
WO2004110388A2 (en) 2004-12-23
EP1644026A4 (en) 2007-10-24
US20050059689A1 (en) 2005-03-17
EP1644026A2 (en) 2006-04-12
CA2528160A1 (en) 2004-12-23
WO2004110387A2 (en) 2004-12-23
CA2528160C (en) 2012-01-03
WO2004110389A2 (en) 2004-12-23
JP2007500757A (ja) 2007-01-18
WO2004110389A3 (en) 2005-12-22
EP1635805A2 (en) 2006-03-22
WO2004110388A3 (en) 2005-07-28
US7863272B2 (en) 2011-01-04
US20050020483A1 (en) 2005-01-27
US20050032827A1 (en) 2005-02-10
US20110082154A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
JP4963607B2 (ja) 神経再生及び機能回復のためのシグマリガンド
US20110015209A1 (en) Sigma ligands for neuronal regeneration and functional recovery
US20110152284A1 (en) Sigma ligands for neuronal regeneration and functional recovery
KR101783632B1 (ko) 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
JP2020530847A (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
EA013084B1 (ru) Модуляторы метаболизма и лечение связанных с ним нарушений
WO2011107583A1 (en) Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20200297696A1 (en) P38 inhibitors for the treatment of fshd
US11583543B2 (en) Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity
JP5301474B2 (ja) ４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン塩の液体製剤
WO2023170550A1 (en) Polymorph forms of aticaprant for use in treating major depressive disorder
CN100420483C (zh) 用于神经元再生和功能恢复的σ配体
WO2008060271A1 (en) Sigma ligands for neuronal regeneration and functional recovery
HK1131862A (en) Sigma ligands for neuronal regeneration and functional recovery
WO2007002885A2 (en) Compositions and methods for use of a sodium channel blocker
HK40105387A (zh) 用於治疗红细胞增多症的组合物和方法
WO2011000562A1 (en) Eltoprazine for the treatment of certain movement disorders
JP2012528881A (ja) 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法
JP2007533699A (ja) 医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120326

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120326

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150406

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees